Advancing Cancer Diagnostics, Improving Lives
From translational research to patient treatment, we envision a world where comprehensive insights enrich cancer diagnosis and offer reassurance to all patients.
News & Events
Update on Leica Biosystems Progress Toward In Vitro Diagnostics Regulation (IVDR) Compliance
Leica Biosystems is pleased to announce its latest update for In Vitro Diagnostics Regulation (IVDR) certification from the notified body BSI for the immunohistochemistry (IHC) portfolio.
Leica Biosystems Launches BOND-PRIME Advanced Staining Solution to Accelerate Diagnostic Productivity
Powered by Universal Access, BOND-PRIME Enables Labs to Seamlessly Adapt to Any Incoming Workflows NUSSLOCH, Germany (April 19) – Leica Biosystems announce the European launch of BOND-PRIME.
Leica Biosystems Strengthens Portfolio with FDA Clearance of Class II Mismatch Repair (MMR) Panel
The BOND MMR Antibody Panel is now available for clinical use on BOND-III and BOND-MAX Immunohistochemistry (IHC) automated instruments.
Leica Biosystems at a Glance
150+ Years of Innovation
2012 - Present
New Era of Science & Technology
2005 - 2011
Global Expansion Accelerates
1989 - 2004
Structuring for Comprehensive Workflow
1930 - 1988
Novel Products Drive Company Growth
1900 - 1930
Microtomy Technology Advances Amidst Wartime Realities
1872 - 1899
The Creation of the Microtome and the Early Years of R. Jung GMBH
Leica Biosystems is proud to be part of Danaher. Danaher’s science and technology leadership puts Leica Biosystems’ solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.